骨肽联合葡萄糖酸钙治疗糖尿病性骨质疏松的疗效观察(1)
 |
| 第1页 |
参见附件(3864KB，3页)。
【摘要】目的 评价骨肽联合葡萄糖酸钙治疗糖尿病性骨质疏松症的临床疗效。方法 随机将62例患者分为治疗组32例(骨肽联合葡萄糖酸钙)和对照组30例(口服α-D3组)，观察治疗前后临床症状总疗效，积分，骨密度和血生化指标变化。结果 治疗组显效率为46.88%，对照组为30%，有显著性差异(P<0.05)；总有效率和积分变化无显著差异(P>0.05)。双能X线骨密度测定：两组用药后骨密度均有上升，治疗前后治疗组股骨颈、股骨粗隆骨密度有非常显著差异(P<0.01)；腰椎(L2～L4)骨密度无显著性差异(P>0.05)。血生化：两组血清碱性磷酸酶均有显著性差异(P<0.05)；血清钙、血清磷无显著性差异(P>0.05)。结论 骨肽联合葡萄糖酸钙治疗原发性骨质疏松症疗效确切又安全，值得临床推广使用。
【关键词】骨肽联合钙剂 糖尿病 骨质疏松
中图分类号：R681.4 文献标识码：A 文章编号：1005-0515(2012)3-024-02
Clinical observation of the bone peptide Joint calcium gluconate treatment of diabetic osteoporosis
WANG Weiming
(Xinxing County, Guangdong Province, Chinese medicine hospital 527400)
【Abstract】Objective the evaluation ossotide calcium gluconate treatment of diabetic osteoporosis clinical efficacy. Methods 62 patients were randomly divided into treatment group 32 cases the (ossotide calcium gluconate) and a control group of 30 cases (oral alpha-D3 group), the total effect of the clinical symptoms before and after treatment, points, bone mineral density and blood biochemical indices changed. Results The treatment group was 46.88%, and 30% in the control group, significant differences (P <0.05); the total efficiency and integral change was no significant difference (P> 0.05). Dual-energy X-ray bone mineral density: the two groups after treatment bone mineral density increases in both the treatment group before and after treatment of femoral neck, femoral trochanter bone mineral density is a significant difference (P <0.01); lumbar spine (L2 ~ L4) BMD was significantly difference (P> 0.05). Blood chemistry: serum levels of alkaline phosphatase are significant differences (P <0.05); serum calcium, serum phosphorus, a significant difference (P> 0.05). Conclusion The exact the United calcium gluconate ossotide efficacy of the treatment of primary osteoporosis and safe, is worthy of clinical use.
【Key words】Joint ossotide calcium diabetes osteoporosis
糖尿病患者伴有骨细胞的功能、活性及骨转化降低，骨吸收大于骨形成而导致骨质疏松，同时随着社会老龄化的不断发展，原发性骨质疏松症患者逐年增多，由此而引发的骨折率也在上升，严重危害老年人的健康。目前传统中药虽然在临床上已有应用，但是疗效报道不多。我院应用骨肽联合钙剂治疗糖尿病性骨质疏松症，取得了满意的疗效，现报告如下：
1 资料与方法
1.1 临床资料 根据《中药新药临床研究指导原则》诊断标准临床确诊为糖尿病骨质疏松患者62例，随机分为治疗组和对照组，其中治疗组男13例 ......
您现在查看是摘要介绍页，详见PDF附件(3864KB，3页)。